Emmaus Life Scie Stock Price, News & Analysis

Emmaus Life Sciences, Inc. (OTCQX: EMMA) reported a 15% increase in net revenue to $4.9 million for Q3 2022, despite a decrease compared to $5.8 million in Q3 2021. The company faced challenges with production delays but remains optimistic for Q4 sales. Loss from operations decreased to $0.7 million from $1.4 million in Q2 2022. However, total operating expenses fell to $5.1 million from $5.4 million year-over-year, and liquidity issues persist with cash reserves at $1.2 million. Emmaus continues to explore refinancing options to address current liabilities.

Emmaus Life Sciences (OTCQX: EMMA) announced a partnership with Kier (Junior) Spates from the Steve Harvey Morning Show to raise awareness about sickle cell disease (SCD) and promote Endari, its L-glutamine oral powder treatment. This collaboration aims to destigmatize SCD and inform millions of listeners about available treatment options as many SCD patients hesitate to seek help. Endari has been FDA-approved since July 2017 and is indicated for adults and children over five, yet faced challenges in reaching underrepresented communities. The initiative seeks to address healthcare access disparities.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) announced its Q2 2022 financial results, reporting net revenues of $4.3 million, down from $6.5 million in Q2 2021. The company experienced a 33% increase in Q2 revenues from Q1 2022, driven by sales of Endari in the U.A.E. Net loss for Q2 2022 totaled $8.9 million or $0.18 per share, compared to a net income of $2.5 million in Q2 2021. Operating expenses decreased slightly to $5.3 million. The company reported cash and cash equivalents of $1.0 million as of June 30, 2022, and is exploring debt restructuring.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) has engaged Acorn Management Partners to enhance investor awareness among financial professionals. This collaboration aims to broaden Emmaus's investor base in the U.S. and the Middle East North Africa region. Emmaus, a leader in sickle cell disease treatment, markets the FDA-approved Endari® (L-glutamine oral powder). Acorn’s expertise in investor relations and their strategic outreach program will support Emmaus's goal to deliver its innovative therapies effectively.

Emmaus Life Sciences, Inc. (OTCQX: EMMA), based in Torrance, California, will participate in two investor conferences in May 2022. The first event, the Q2 Investor Summit, will occur on May 3-4, where CEO Yutaka Niihara will present at 3:30 p.m. ET. The H.C Wainwright Global Investment Conference is scheduled for May 23-26, with an on-demand presentation available from May 24, 2022, at 7:00 a.m. ET. One-on-one meetings can be arranged with management during both conferences.

Emmaus Life Sciences (OTQXC: EMMA) has launched a full-service telehealth solution to enhance access to its product Endari®, an L-glutamine oral powder for sickle cell disease treatment. This initiative, in partnership with Asembia LLC, US Bioservices Corporation, and UpScript IP Holdings, enables patients to receive prescriptions and home delivery, improving patient experience and adherence rates. With the telehealth market experiencing significant growth, Emmaus aims to reach new patients and generate revenue through this innovative service.

Emmaus Life Sciences (OTCQX: EMMA) reported significant findings from a study on Endari®, an oral L-glutamine powder, in treating sickle cell disease. Conducted in French Guiana and Qatar, the observational study showed that patients had fewer vaso-occlusive crises and hospitalizations over 72 weeks compared to baseline, with statistically significant reductions in blood transfusions and improved hemoglobin levels. The study, presented at the 62nd Annual Meeting of the British Society for Haematology, reinforces the effectiveness of Endari in enhancing patient outcomes for sickle cell disease.

Emmaus Life Sciences announced that Florida has approved the inclusion of Endari, its prescription-grade L-glutamine oral powder, on the Medicaid Preferred Drug List (PDL) starting April 1, 2022. This decision means Endari can be prescribed without prior authorization, streamlining access for patients suffering from sickle cell disease. Florida joins several other states in eliminating prior authorization for this medication. CEO Yutaka Niihara emphasized that this approval brings them closer to making Endari widely available to healthcare providers.

On March 23, 2022, Emmaus Life Sciences announced the U.A.E. Ministry of Health approved its marketing application for Endari®, a treatment for sickle cell disease. After a five-month review, Endari was previously available only on an early access basis. Emmaus estimates about 600 sickle cell patients reside in the U.A.E. and approximately 225,000 in the MENA region could benefit from the drug. The company aims to secure further approvals across Gulf Cooperation Council states, highlighting the significance of this market due to the higher prevalence of sickle cell disease compared to the U.S.